TriStrata Accuses ICN of Infringing Patents
ICN Pharmaceuticals Inc., maker of the hepatitis drug ribavirin, was accused in a lawsuit by rival TriStrata Technology Inc. of infringing patents for wrinkle treatments.
TriStrata, a unit of closely held Princeton, N.J.-based NeoStrata Co., claims that ICN is wrongly using its alpha hydroxy acid skin-care inventions.
ICN sells products including the Gly Derm line that infringe five TriStrata-owned patents awarded since 1992, according to the federal court lawsuit filed Monday in Wilmington, Del.
ICN did not comment on the suit.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
